Breast Cancer with a Newly Diagnosed Variant in the PTEN Gene: A Case Report

Abstract

INTRODUCTION: The phosphatase and tensin homolog hamartoma tumor syndrome (PHTS) refers to a spectrum of disorders caused by variants of the phosphatase and tensin homolog (PTEN) gene, including Cowden syndrome (CS), Bannayan–Riley–Ruvalcaba syndrome, adult Lhermitte–Duclos disease, and autism spectrum disorders associated with macrocephaly. PHTS is characterized by hamartomas in multiple organs and is associated with an increased risk of developing malignant tumors including, breast, thyroid, endometrial, colorectal, and kidney tumors. Breast cancer is the most common malignancy associated with PHTS.

CASE PRESENTATION: We describe the case of a 44-year-old female patient with invasive ductal carcinoma of the right breast. Cobblestone papillomatosis was present in the gingiva. She had a medical history of bilateral adenomatous goiters for 10 years. Her mother had been diagnosed with breast cancer, thyroid and tongue tumors, gastric polyps, hepatic hemangioma, and collagen disease. Additionally, the patient’s maternal grandmother had a history of colon cancer. Based on the patient’s family history and physical findings, CS was suspected, and direct DNA sequencing analysis revealed a haplotype c.634del mutation in exon 7 of the PTEN gene. Although there is no clear evidence supporting risk-reducing surgery for PHTS, a right nipple-sparing mastectomy, sentinel lymph node biopsy, and tissue expander reconstruction were performed.

CONCLUSIONS: We report a case of breast cancer with a newly diagnosed c.634del mutation in the PTEN gene. We also reviewed the current literature on PTEN genetic variants and breast cancer subtypes.

Abbreviations

NCCN

National Comprehensive Cancer Network

PHTS

PTEN hamartoma tumor syndrome

PTEN

phosphatase and tensin homolog

CS

Cowden syndrome

LDD

Lhermitte–Duclos disease

INTRODUCTION

The phosphatase and tensin homolog hamartoma tumor syndrome (PHTS) refers to a spectrum of disorders caused by variants of the phosphatase and tensin homolog (PTEN) gene, including Cowden syndrome (CS), Bannayan–Riley–Ruvalcaba syndrome, adult Lhermitte–Duclos disease (LDD), and autism spectrum disorders associated with macrocephaly. CS is characterized by multiple hamartomas and carries a high risk of both benign and malignant tumors of the breast, thyroid, endometrium, colorectum, and kidneys.¹⁾ The most common malignancy associated with PHTS is breast cancer, with a reported lifetime risk of 85%.²⁾ Here, we report a case of breast cancer with a novel mutation in the PTEN gene.

CASE PRESENTATION

A 44-year-old woman was referred to our hospital because of a right breast tumor identified during a medical checkup. Mammography revealed no tumor or calcification in either breast. However, ultrasonography revealed an irregular hypoechoic mass (22 × 19 × 9 mm) in the right breast (Fig. 1). Dynamic contrast-enhanced magnetic resonance imaging showed an enhanced, irregular mass in the right breast (Fig. 2). Fluorodeoxyglucose positron emission tomography revealed abnormal resorption in the right breast and uterus (Fig. 3). Abnormal resorption in the uterus was diagnosed as a uterine myoma on computed tomography. A core needle biopsy revealed an invasive ductal carcinoma that was estrogen receptor (ER) positive, progesterone receptor (PR) positive, and human epidermal receptor 2 (HER2) negative. She had a medical history of bilateral adenomatous goiters for 10 years. Cobblestone papillomatosis was present in the gingiva (Fig. 4). Her mother had been diagnosed with breast cancer, thyroid and tongue tumors, gastric polyps, hepatic hemangioma, and collagen disease. Additionally, her maternal grandmother had been diagnosed with colon cancer. Owing to her family history and physical findings, CS was suspected. The diagnosis of CS was based on the criteria of the National Comprehensive Cancer Network (NCCN).³⁾ In this case, breast cancer and oral papilloma met the major criteria, and thyroid structural lesions met the minor criteria; however, the diagnostic criteria for CS were not met. Despite this, due to the strong suspicion of CS based on her mother’s medical history, genetic testing was performed prior to surgery. From an ethical perspective, professional genetic counseling was provided to the patient and her family, and informed consent for genetic testing was obtained. A direct DNA sequencing analysis was performed, and a haplotype c.634del mutation in exon 7 of the PTEN gene was detected (Fig. 5). This mutation resulted in a p.Asn212Ilefs*9 substitution. Based on the results of the genetic test, she was diagnosed with PHTS.

Fig. 1 (A) Mammography showed no tumor or calcification in her bilateral breast. (B) Ultrasonography showed a circumscribed, irregular hypoechoic mass in her right breast.

Fig. 2 Contrast-enhanced magnetic resonance imaging showed an enhanced irregular mass in the right breast.

Fig. 3 Fluorodeoxyglucose-positron emission tomography showed abnormal resorption in her right breast (arrowhead) and uterus (arrow).

Fig. 4 Papillomatosis in a cobblestone was present on her gingivae.

Fig. 5 A direct DNA sequencing analysis showed a haplotype c.634del mutation of the PTEN gene.

Although there is no clear evidence for risk-reducing surgery in PHTS, a nipple-sparing mastectomy, sentinel lymph node biopsy, and tissue expander reconstruction were performed. Histopathological examination confirmed an invasive ductal carcinoma measuring 1.8 × 1.0 cm with no lymph node metastasis (Fig. 6). The histological grade was II. Immunohistochemistry revealed ER- and PR-positive staining, HER-2-negative status, and Ki-67-positive staining of 15%. Aromatase inhibitor therapy was started as adjuvant therapy. Five months after breast cancer surgery, the patient underwent a laparoscopic total hysterectomy and bilateral salpingo-oophorectomy, and the histopathological diagnosis was atypical endometrial hyperplasia.

Fig. 6 Histopathological examination of the right breast tumor ×200. (A) Hematoxylin and eosin staining shows an invasive ductal carcinoma with histological grade II. Immunohistochemistry revealed ER positive (B) and PR positive (C).

DISCUSSION

The PTEN gene has two main domains: the N-terminal region, which includes the phosphatase domain, containing the PTEN active site in exon 5, and the C-terminal region, which includes the C2 domain, that binds to phospholipids and positions the catalytic domain on the membrane.⁴⁾ According to a study investigating cancer risk and genotype–phenotype correlations in 22 Japanese patients with CS, 12 had N-terminal-PTEN variants (11 in the phosphatase domain) and 10 had C-terminal-PTEN variants (C2 domain). Cancer was found in 33.3% (4/12) of the patients in the N-terminal region group (27.3% [3/11] in the phosphatase domain) and 80.0% (8/10) of those in the C2 domain group. The incidence of cancer in the C2 domain group was significantly higher than that in the N-terminal region (p = 0.038) and phosphatase domain (p = 0.023) groups. Breast cancer was found in 100% (7/7) of female patients in the C2 domain group and 50.0% (4/8) of those in the N-terminal group (42.9% [3/7] of those in the phosphatase domain group). The incidence of breast cancer in the C2 domain group was marginally higher than that in the N-terminal region group (p = 0.051).⁵⁾

Pathogenic variants of the PTEN gene may include large deletions, small intragenic deletions/insertions and missense, nonsense, and splice site variants, and these have been described in all nine exons of the gene.^2,6–8) Unlike other genes, virtually all germline PTEN missense mutations in the coding region are believed to be pathogenic.^6,9) Furthermore, no clear genotype–phenotype correlation has been found in PHTS, although several studies have examined the correlation between CS phenotypes and PTEN gene variant sites.^2,4,10,11)

The c.634del mutation in the C2 domain has not previously been reported in PHTS. Germline PTEN-related breast cancer is characterized by a high incidence of hormone receptor-positive cases, the progression tends to be slow, and the prognosis is not poor.⁵⁾

On the other hand, somatic PTEN mutation has been reported to be associated with triple-negative breast cancers.¹²⁾ The literature describing both PTEN variants and breast cancer subtypes is presented in Table 1. Hormone receptor-positive cases were the most common, including the present case (8 out of 12 cases), whereas 3 and 1 cases were triple negative and HER2 positive, respectively.^13–22)

Table 1Expression of hormone receptor of breast cancer and PTEN mutations in PHTS

Age	Sex	ER	PgR	HER2	Pathology	Bilateral	Exon	Nucleotide change	Variant type	Reference
32	F	+	+	–	IDC	+	1	c.71A>T	Missense	Pradella et al., 201413)
33	F	+	+	–	IDC	+	5	p.R130*(c.388C>T)	Nonsense	Nara et al., 201714)
29	F	+	NA	–	IDC	+	5	p.R130Q(c.389G>A)	Missense	Chandhanayingyong et al., 201515)
57	F	–	–	–	Mucinous	–	7	c.697C>T	Nonsense	Gosein et al., 201616)
34	F	+	NA	–	IDC	–	7	c.698_701delGACCinsAA	NA	Walsh et al., 201117)
29	F	–	–	–	IDC	+	7	c.723dupT	Nonsense	Won et al., 201918)
35	F	+	+	–	DCIS	–	7	c.723dupT	Nonsense	Nara et al., 201714)
41	M	+	NA	NA	IDC	–	7	c.802delG	Splicing	Fackenthal et al., 200119)
35	F	–	–	–	IDC	–	8	c.823_840del.18	Nonsense	Sueta et al., 202220)
44	F	+	+	–	IDC	+	9	c.1027-2A>G	Splicing	Peiró et al., 201021)
38	F	–	–	+	IDC	–	NA	Mutation	NA	Sabaté et al., 200622)
44	F	+	+	–	IDC	–	7	c.634del	Frameshift	This case

NA, not assessed; IDC, invasive ductal carcinoma; DCIS, ductal carcinoma in situ.

PHTS is a rare autosomal dominant hereditary disorder caused by germline variants of the PTEN gene located on chromosome 10q23.^6,23,24) PTEN participates in the negative regulation of the phosphoinositide 3-kinase-protein kinase B and mammalian target of rapamycin signaling pathways, controlling cell proliferation and cell cycle progression and promoting apoptosis.²⁵⁾ Thus, the loss-of-function mutation of PTEN correlates with the development of various human cancers. In recent studies, it has been found that target the cellular alterations caused by PTEN pathogenic variants.²⁶⁾ Pharmacologic mTOR inhibitors (like everolimus and sirolimus) are being studied for their potential to reduce oncologic risk. Additionally, there is a hypothesis that poly (ADP-ribose) polymerase (PARP) inhibitors may also be effective for PTEN pathogenic variant carriers, similar to their use in BRCA-related breast cancers. However, more research is needed to effectively translate these strategies into prevention and treatment options. The cumulative lifetime risk of any cancer in patients with CS is 89%, with morbidities including 85% for breast cancer, 32% for LDD, 21% for thyroid cancer, 19% for endometrial cancer, 16% for colorectal cancer, and 15% for renal cancer.^2,27) Nevertheless, the most typical features are specific mucocutaneous lesions, including trichilemmomas, acral keratoses, and oral papillomatous papules, which occur in 90%–100% of patients with CS.

Cancer surveillance should be performed for individuals with positive findings on genetic testing and those with negative findings on genetic testing but meeting the clinical diagnostic criteria. The NCCN guideline recommends breast self-examination beginning at the age of 18 years, annual clinical breast examinations starting at the age of 25 years, and mammography and breast magnetic resonance imaging (MRI) at 30–35 years of age (or 5–10 years before a family’s earliest known breast cancer diagnosis).²⁸⁾ Given the 85% risk of developing breast cancer, the possibility of risk-reducing mastectomy should be considered. Counseling should include discussions on the degree of protection, reconstruction options, and associated risks. While options like nipple-sparing mastectomy show promise based on BRCA data, the effectiveness of chemoprevention in PTEN pathogenic variant carriers remains unclear. Overall, further research is essential to improve outcomes and clarify treatment strategies for this population.²⁶⁾ Early detection and surveillance of PTEN-related hereditary cancers is done with established imaging modalities such as ultrasound and MRI (Table 2). In the present case, the patient should undergo future surveillance of the left breast, thyroid, kidneys, and colon including annual MRI and mammography for breast evaluation, annual ultrasound for thyroid assessment, ultrasound every 1–2 years for renal cancer surveillance, and a colonoscopy every 5 years for colorectal cancer screening.

Table 2Guideline summary: cancer surveillance protocol for individuals with PTEN hamartoma tumor syndrome

	Surveillance	Interval	From age
Breast cancer	Breast self-examination	Every 1 year	18
	MRI	Every 1 year	30
	Mammography	Every 1 year	30–35
	Risk-reducing surgery offered	–	–
Thyroid cancer	Ultrasound	Every 1 year	Age at diagnosis
Renal cancer	Ultrasound	Every 1–2 years	40
Colorectal cancer	Baseline colonoscopy	Every 5 years	35–40
Melanoma	Baseline skin examination	–	30
Endometrial cancer	The presence or absence of abnormal bleeding/endometrial biopsy※	–	–

^※This should include endometrial biopsy every 1–2 years if abnormal uterine bleeding or postmenopausal bleeding occurs.

CONCLUSION

Herein, we report a case of breast cancer with a newly diagnosed c.634del mutation in the PTEN gene. Because the patient was diagnosed with PHTS before breast cancer surgery, we were able to discuss the breast surgery procedure resulting in her undergoing a right nipple-sparing mastectomy. We also reviewed the current literature on PTEN genetic variants and breast cancer subtypes.

ACKNOWLEDGMENTS

The authors thank all those who contributed to this report.

DECLARATIONS

Funding

This study did not receive any specific grants from funding agencies in the public, commercial, or non-profit sectors.

Authors’ contributions

YM and HJ performed the surgical procedures.

All the authors have read and approved the final version of the manuscript.

Availability of data and materials

The data are not available for public access due to patient privacy concerns but are available from the corresponding author upon reasonable request.

Ethics approval and consent to participate

Ethics approval: All procedures involving human participants were performed in accordance with the ethical standards of the Institutional Review Board of Teikyo University Hospital and the 1964 Helsinki Declaration and its later amendments.

Consent for publication

Informed consent was obtained from the patient for the publication of this report.

Competing interests

The authors declare that they have no competing interests.

REFERENCES

• 1)  Pilarski R, Burt R, Kohlman W, et al. Cowden syndrome and the PTEN hamartoma tumor syndrome: systematic review and revised diagnostic criteria. J Natl Cancer Inst 2013; 105: 1607–16.
• 2)  Tan MH, Mester JL, Ngeow J, et al. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res 2012; 18: 400–7.
• 3)  NCCN guidelines. Genetic/familial high-risk assessment: breast and ovarian, version 3. 2019, 2019. https://www2.tri-kobe.org/nccn/guideline/gynecological/english/genetic_familial.pdf#search=%27NCCN+guidline%2C+hereditary+and+familial+breast+and+ovarian%27.
• 4)  Bubien V, Bonnet F, Brouste V, et al. High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome. J Med Genet 2013; 50: 255–63.
• 5)  Teramae S, Muguruma N, Okamoto K, et al. Cancer risk and genotype-phenotype correlation in Japanese patients with Cowden syndrome. Int J Clin Oncol 2022; 27: 639–47.
• 6)  Tan MH, Mester J, Peterson C, et al. A clinical scoring system for selection of patients for PTEN mutation testing is proposed on the basis of a prospective study of 3042 probands. Am J Hum Genet 2011; 88: 42–56.
• 7)  Ngeow J, Stanuch K, Mester JL, et al. Second malignant neoplasms in patients with Cowden syndrome with underlying germline PTEN mutations. J Clin Oncol 2014; 32: 1818–24.
• 8)  Mester J, Eng C. When overgrowth bumps into cancer: the PTEN-opathies. Am J Med Genet C Semin Med Genet 2013; 163: 114–21.
• 9)  Zbuk KM, Eng C. Cancer phenomics: RET and PTEN as illustrative models. Nat Rev Cancer 2007; 7: 35–45.
• 10)  Nieuwenhuis MH, Kets CM, Murphy-Ryan M, et al. Cancer risk and genotype-phenotype correlations in PTEN hamartoma tumor syndrome. Fam Cancer 2014; 13: 57–63.
• 11)  Leslie NR, Longy M. Inherited PTEN mutations and the prediction of phenotype. Semin Cell Dev Biol 2016; 52: 30–8.
• 12)  Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61–70.
• 13)  Pradella LM, Evangelisti C, Ligorio C, et al. A novel deleterious PTEN mutation in a patient with early-onset bilateral breast cancer. BMC Cancer 2014; 14: 70.
• 14)  Nara M, Ishida N, Hagio K, et al. Two cases of breast cancer in juvenile patients in their thirties with pten hamartoma tumor syndrome. J Jpn Surg Assoc 2017; 78: 2624–8. (in Japanese)
• 15)  Chandhanayingyong MC, Bernthal NM, Ungarreevittaya P, et al. Ewing sarcoma in a patient with Cowden syndrome. J Natl Compr Canc Netw 2015; 13: 1310–4.
• 16)  Gosein MA, Narinesingh D, Nixon CA-AC, et al. Multi-organ benign and malignant tumors: recognizing Cowden syndrome: a case report and review of the literature. BMC Res Notes 2016; 9: 388.
• 17)  Walsh S, Carter M, Tubridy N, et al. Lhermitte-Duclos and Cowden diseases: breast cancer as an unusual initial presentation of these overlapping conditions. BMJ Case Rep 2011; 2011: bcr0820114730.
• 18)  Won HS, Chang ED, Na SJ, et al. PTEN mutation identified in patient diagnosed with simultaneous multiple cancers. Cancer Res Treat 2019; 51: 402–7.
• 19)  Fackenthal JD, Marsh DJ, Richardson AL, et al. Male breast cancer in Cowden syndrome patients with germline PTEN mutations. J Med Genet 2001; 38: 159–64.
• 20)  Sueta A, Takeno M, Goto-Yamaguchi L, et al. A progressive and refractory case of breast cancer with Cowden syndrome. World J Surg Oncol 2022; 20: 279.
• 21)  Peiró G, Adrover E, Guijarro J, et al. Synchronous bilateral breast carcinoma in a patient with Cowden syndrome: a case report with morphologic, immunohistochemical and genetic analysis. Breast J 2010; 16: 77–81.
• 22)  Sabaté JM, Gómez A, Torrubia S, et al. Evaluation of breast involvement in relation to Cowden syndrome: a radiological and clinicopathological study of patients with PTEN germ-line mutations. Eur Radiol 2006; 16: 702–6.
• 23)  Nelen MR, Padberg GW, Peeters EA, et al. Localization of the gene for Cowden disease to chromosome 10q22-23. Nat Genet 1996; 13: 114–6.
• 24)  Pilarski R, Stephens JA, Noss R, et al. Predicting PTEN mutations: an evaluation of Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome clinical features. J Med Genet 2011; 48: 505–12.
• 25)  Stambolic V, Suzuki A, de la Pompa JL, et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998; 95: 29–39.
• 26)  Williams AD, LaRoy J, Le T, et al. Clinical challenges in breast care for patients with PTEN pathogenic variants: a case series and literature review. Surg Oncol Insight 2024; 1: 100016.
• 27)  Riegert-Johnson DL, Gleeson FC, Roberts M, et al. Cancer and Lhermitte-Duclos disease are common in Cowden syndrome patients. Hered Cancer Clin Pract 2010; 8: 6.
• 28)  NCCN clinical practice guidelines in oncology. Genetic/familial high-risk assessment: breast, ovarian, and pancreatic, version 3. 2024, 2024. https://www.nccn.org/guidelines/guidelines-detail?category=2&id=1503.